Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $4.1 million.

  • C4 Therapeutics' Cash from Investing Activities rose 242222.22% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.3 million, marking a year-over-year increase of 18556.74%. This contributed to the annual value of -$51.3 million for FY2024, which is 13237.78% down from last year.
  • C4 Therapeutics' Cash from Investing Activities amounted to $4.1 million in Q3 2025, which was up 242222.22% from $38.9 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Cash from Investing Activities high stood at $57.7 million for Q3 2023, and its period low was -$100.6 million during Q3 2021.
  • In the last 5 years, C4 Therapeutics' Cash from Investing Activities had a median value of $13.7 million in 2024 and averaged $2.5 million.
  • As far as peak fluctuations go, C4 Therapeutics' Cash from Investing Activities tumbled by 3344891.3% in 2021, and later surged by 242222.22% in 2025.
  • C4 Therapeutics' Cash from Investing Activities (Quarter) stood at -$59.4 million in 2021, then soared by 115.63% to $9.3 million in 2022, then skyrocketed by 244.09% to $31.9 million in 2023, then crashed by 57.21% to $13.7 million in 2024, then tumbled by 70.11% to $4.1 million in 2025.
  • Its last three reported values are $4.1 million in Q3 2025, $38.9 million for Q2 2025, and $29.1 million during Q1 2025.